P-209P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. (20th June 2018) - Puzzoni, M; Demurtas, L; Ziranu, P; Lai, E; Giampieri, R; Faloppi, L; Mandolesi, A; Cremolini, C; Masi, G; Gelsomino, F; Mariani, S; Cubeddu, A; et al.